NIH VideoCast - Systemic immunity protects the mind: Can immune checkpoint blockade combat Alzheimer’s disease?

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Systemic immunity protects the mind: Can immune checkpoint blockade combat Alzheimer’s disease?

Loading... Loading video...

500 Views

Air date:	Wednesday, October 11, 2017, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 500 (225 Live, 275 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:00:13
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director's Wednesday Afternoon Lecture It is now widely accepted that immune surveillance is required for supporting brain functional plasticity and repair. Participating cells include the microglia, the resident myeloid immune cells of the brain, circulating monocytes, and CD4+ T cells. Over the years, we demonstrated that leukocytes supporting the brain can gain access to the brain through a unique compartment within the brain territory, the chroid plexus epithelium (CP) at the blood-cerebrospinal fluid-barrier (B-CSF-B), remote from the brain parenchyma. The CP serves as a selective gateway allowing leukocyte entry to the CNS; its activity is controlled by its cytokine milieu, and specifically by IFN-g. We showed that in mouse models of aging and in Alzheimer’s disease (AD), this interface is suppressed in its ability to allow communication between the brain and the circulating leukocytes. We further found that transiently relieving systemic immune suppression could enhance recruitment of disease-modifying leukocytes to sites of brain pathology. Unleashing the immune system could be achieved by blocking inhibitory immune checkpoints, regulatory pathways that normally maintain systemic immune homeostasis and tolerance. Specifically, we found in three mouse models of AD that targeting the inhibitory checkpoints, PD-1/PD-L1 pathway, was effective in reversing cognitive loss, reducing brain inflammation, and mitigating disease pathology. In addition, our emerging understanding of the fate of microglia in AD, based on single cell immunogenomics, has revealed a role of microglia in combating the disease, and suggests that boosting systemic immunity modifies microglial activity. Overall, our results indicate that targeting the immune system rather than brain-specific disease-escalating factors may provide a multi-dimensional therapy for AD. For more information go to https://oir.nih.gov/wals/2017-2018/systemic-immunity-protects-mind-can-immune-checkpoint-blockade-combat

NLM Title:	Systemic immunity protects the mind : can immune checkpoint blockade combat Alzheimer's disease? / Michal Schwartz.
Author:	Schwartz, Michal. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): It is now widely accepted that immune surveillance is required for supporting brain functional plasticity and repair. Participating cells include the microglia, the resident myeloid immune cells of the brain, circulating monocytes, and CD4+ T cells. Over the years, we demonstrated that leukocytes supporting the brain can gain access to the brain through a unique compartment within the brain territory, the chroid plexus epithelium (CP) at the blood-cerebrospinal fluid-barrier (B-CSF-B), remote from the brain parenchyma. The CP serves as a selective gateway allowing leukocyte entry to the CNS; its activity is controlled by its cytokine milieu, and specifically by IFN-g. We showed that in mouse models of aging and in Alzheimer"s disease (AD), this interface is suppressed in its ability to allow communication between the brain and the circulating leukocytes. We further found that transiently relieving systemic immune suppression could enhance recruitment of disease-modifying leukocytes to sites of brain pathology. Unleashing the immune system could be achieved by blocking inhibitory immune checkpoints, regulatory pathways that normally maintain systemic immune homeostasis and tolerance. Specifically, we found in three mouse models of AD that targeting the inhibitory checkpoints, PD-1/PD-L1 pathway, was effective in reversing cognitive loss, reducing brain inflammation, and mitigating disease pathology. In addition, our emerging understanding of the fate of microglia in AD, based on single cell immunogenomics, has revealed a role of microglia in combating the disease, and suggests that boosting systemic immunity modifies microglial activity. Overall, our results indicate that targeting the immune system rather than brain-specific disease-escalating factors may provide a multi-dimensional therapy for AD.
Subjects:	Alzheimer Disease--immunology Alzheimer Disease--therapy Immunotherapy--methods
Publication Types:	Lecture Webcast

NLM Classification:	WT 155
NLM ID:	101716391
CIT Live ID:	26478
Permanent link:	https://videocast.nih.gov/watch=26478

Related Videos...